NCT03246529 · OUTCOME

Annualized Relapse Rate Until September 2028

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM) · Source last updated 2026-01-15

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: End of Study

What was measured

Comparability between the effect of BL-8040 + G-CSF and placebo + G-CSF on Annualized Relapse Rate until September 2028

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2029-06
denom Units Selected: Participants
description: Comparability between the effect of BL-8040 + G-CSF and placebo + G-CSF on Annualized Relapse Rate until September 2028
reporting Status: NOT_POSTED
time Frame: End of Study
title: Annualized Relapse Rate Until September 2028
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice